Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins

Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins Recombinant glycoproteins produced in animal cell lines often bear the nonhuman sialic acid N-glycolylneuraminic acid (Neu5Gc). Ghaderi et al. show that two monoclonal antibodies in clinical use differ with respect to addition of Neu5Gc and propose that drug developers should consider the consequences of the Neu5Gc modification. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Nature Biotechnology Springer Journals

Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins

Loading next page...
 
/lp/springer-journals/implications-of-the-presence-of-n-glycolylneuraminic-acid-in-0g0q1ylnkX

References (41)

Publisher
Springer Journals
Copyright
Copyright © 2010 by Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.
Subject
Life Sciences; Life Sciences, general; Biotechnology; Biomedicine, general; Agriculture; Biomedical Engineering/Biotechnology; Bioinformatics
ISSN
1087-0156
eISSN
1546-1696
DOI
10.1038/nbt.1651
Publisher site
See Article on Publisher Site

Abstract

Recombinant glycoproteins produced in animal cell lines often bear the nonhuman sialic acid N-glycolylneuraminic acid (Neu5Gc). Ghaderi et al. show that two monoclonal antibodies in clinical use differ with respect to addition of Neu5Gc and propose that drug developers should consider the consequences of the Neu5Gc modification.

Journal

Nature BiotechnologySpringer Journals

Published: Jul 25, 2010

There are no references for this article.